A large randomized clinical trial shows significant reduction in urinary tract infections

Report this content

A recently published, randomized, controlled multicenter study in India shows that urinary catheters with Bactiguard's coating for infection prevention reduce the risk of catheter-associated urinary tract infections (CAUTI) by 69% compared to standard catheters.

“We are very proud to be able to present such fine results from the largest randomized, controlled study done so far on Bactiguard's urinary catheters. Nearly 70 percent reduction is an effectiveness that many pharmaceuticals won’t even come close to. In addition to showing a major general reduction in the risk of infection, the study provides new information on how effective our technology is in an environment where infections caused by multi-resistant bacteria is a major problem, "says Stefan Grass, Chief Medical Officer at Bactiguard.

The study has just been published in the internationally renowned scientific journal "Antimicrobial resistance and infection control”1. A total of 1,000 patients were randomly assigned to a standard catheter or a urinary catheter with Bactiguard's coating for infection prevention. The group that received the Bactiguard catheter had a 69% lower risk of developing catheter-associated urinary tract infections (CAUTI) during the treatment period. In addition, no side effects related to Bactiguard's technology were reported.

Catheter-related urinary tract infection is the most common healthcare-associated infection and often caused by indwelling urinary catheters. The infections can lead to serious complications that cause great suffering to the patient, higher mortality and increased healthcare costs. Urinary catheters with Bactiguard's unique coating have a well-documented ability to reduce symptomatic urinary tract infections.

Link to the study: https://doi.org/10.1186/s13756-021-00907-w

1. Kai-Larsen, Y., Grass, S., Mody, B. et al. Foley catheter with noble metal alloy coating for preventing catheter-associated urinary tract infections: a large, multi-center clinical trial. Antimicrob Resist Infect Control 10, 40 (2021). Publisher: Springer Nature. https://doi.org/10.1186/s13756-021-00907-w

For further information, please contact:
Stefan Grass, Chief Medical Officer and deputy CEO, mobile +46 70 725 24 48

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes Hydrocyn® aqua, a non-alcoholic product line for wound care and disinfection. Hydrocyn effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.

Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com